Adlai Nortye Ltd. reports clinical-stage biotechnology developments for an oncology pipeline focused on RAS-targeting therapies and next-generation cancer immunotherapies. Company updates include clinical and research activity for AN9025, an oral pan-RAS(ON) inhibitor, AN4035, a CEACAM5-targeting antibody-drug conjugate with a pan-RAS(ON) inhibitor payload, AN8025, a tri-functional fusion protein, and AN4005, an oral small-molecule PD-L1 inhibitor.
Recurring news for ANL also covers scientific presentations, license agreements, private-placement financing, shareholder and governance matters, investor conference participation, and American depositary share capital-structure disclosures tied to the company’s foreign-issuer reporting profile.
Summary not available.
Summary not available.
Summary not available.
Summary not available.